Search: WFRF:(Moliterno David J.)
> (2015-2018)
> (2015)
> Leonardi Sergio >
Glycoprotein IIb/II...
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)
-
Cornel, Jan H. (author)
-
Tricoci, Pierluigi (author)
-
Lokhnygina, Yuliya (author)
-
show more...
-
Moliterno, David J. (author)
-
- Wallentin, Lars (author)
- Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)
-
Armstrong, Paul W. (author)
-
Aylward, Philip E. (author)
-
Clare, Robert M. (author)
-
Chen, Edmond (author)
-
Leonardi, Sergio (author)
-
de Werf, Frans Van (author)
-
White, Harvey D. (author)
-
- Held, Claes (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
Strony, John (author)
-
Mahaffey, Kenneth W. (author)
-
Harrington, Robert A. (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2015
- 2015
- English.
-
In: American Journal of Cardiology. - : Elsevier BV. - 0002-9149 .- 1879-1913. ; 115:10, s. 1325-1332
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- We evaluated the interaction between protease-activated receptor-1 antagonist vorapaxar and concomitant glycoprotein (GP) IIb/IIIa receptor inhibitors in patients with non-ST-segment elevation acute coronary syndromes who underwent PCI. In Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial, 12,944 patients with non-ST-segment elevation acute coronary syndromes were randomized to vorapaxar or placebo. Administration of GP IIb/IIIa receptor inhibitors was allowed at the treating physician's discretion. We investigated whether use of GP IIb/IIIa receptor inhibitors modified vorapaxar's effect on non-coronary artery bypass grafting (CABG)-related bleeding at 7 days and ischemic events at 30 days. In total, 7,455 patients underwent PCI during index hospitalization. Of these, 2,023 patients (27.1%) received inhibitors and 5,432 (72.9%) did not. Vorapaxar was associated with a numerically higher rate of non-CABG-related moderate/severe Global Use of Strategies to Open Occluded Arteries (GUSTO) bleeding at 7 days compared with placebo in those who did (1.3% vs 1.0%) and did not (0.6% vs 0.4%) receive GP IIb/IIIa receptor inhibitors. Ischemic end point rates at 30 days were not significantly lower with vorapaxar versus placebo. Increased rates of non-CABG GUSTO moderate/severe bleeding were observed in patients who received GP IIb/IIIa receptor inhibitors versus those who did not (adjusted hazard ratio [HR] 1.77, 95% confidence interval [CI] 0.43 to 7.35 in placebo arm; adjusted HR 2.02, 95% CI 0.62 to 6.61 in vorapaxar arm) and in those who received vorapaxar versus placebo (adjusted HR 1.54, 95% CI 0.36 to 6.56 in the GP IIn/IIIa group; adjusted FIR 1.34, 95% CI 0.44 to 4.07 in the no-GP IIb/IIIa group). No interaction was found between vorapaxar and inhibitor use up to 7 days (P interaction = 0.89) nor at the end of the treatment (P interaction = 0.74); however, the event rate was low. Also, no interaction was observed for efficacy end points after PCI at 30 days or at the end of the treatment. In conclusion, GP IIb/IIIa receptor inhibitor use plus dual antiplatelet therapy in a population with non-ST-segment elevation myocardial infarction planned for PCI was frequent but did not interact with vorapaxar's efficacy or safety. Nonetheless, GP IIb/IIIa receptor inhibitors and vorapaxar were associated with increased bleeding risk, and their combined use may result in additive effects on bleeding rates.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Cornel, Jan H.
-
Tricoci, Pierlui ...
-
Lokhnygina, Yuli ...
-
Moliterno, David ...
-
Wallentin, Lars
-
Armstrong, Paul ...
-
show more...
-
Aylward, Philip ...
-
Clare, Robert M.
-
Chen, Edmond
-
Leonardi, Sergio
-
de Werf, Frans V ...
-
White, Harvey D.
-
Held, Claes
-
Strony, John
-
Mahaffey, Kennet ...
-
Harrington, Robe ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
American Journal ...
- By the university
-
Uppsala University